<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631589</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-SCT-01</org_study_id>
    <nct_id>NCT03631589</nct_id>
  </id_info>
  <brief_title>MSC for Severe aGVHD</brief_title>
  <official_title>Treatment of Steroid-resistant Severe Acute Graft-versus-host Disease With Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Steroid-resistant acute graft-versus-host disease (aGVHD) is one of the most severe
      complications in the setting of allogeneic hematopoietic stem cell transplantation (HSCT),
      which cannot be significant benefit from the second-line therapies.The mesenchymal stem cells
      (MSCs) possess extensive immunomodulatory properties and are very promising to rescue the
      refractory aGVHD.This study aims to assess the efficacy and safety of MSCs for the treatment
      of the refractory aGVHD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete and partial response rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events that are related to treatment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Steroid-resistant Severe aGVHD</condition>
  <arm_group>
    <arm_group_label>MSCs treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSCs</intervention_name>
    <description>mesenchymal stem cells therapy</description>
    <arm_group_label>MSCs treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Aged &lt;65 years

          -  Patients with steroid-resistant severe aGVHD

          -  Cardiac: Left ventricular ejection fraction ≥ 50%

          -  Adequate renal and hepatic function

          -  Performance status: Karnofsky ≥ 70%

        Exclusion Criteria:

          -  Pregnant or lactating females.

          -  Any co-morbidity precluding the administration of MSCs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianda Hu, Prof.M.D.Ph.D</last_name>
    <phone>86-13959169016</phone>
    <email>drjiandahu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianda Hu, Prof.</last_name>
      <phone>86-13959169016</phone>
      <email>drjiandahu@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ting Yang, Prof.</last_name>
      <phone>86-13950210357</phone>
      <email>yang.hopeting@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jianda Hu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Jianda Hu</investigator_full_name>
    <investigator_title>Director of the department of Hematology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

